RxDoctor Payments Data

Aimee Casarez

Family · Albuquerque, NMNPI 1568135432

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (50.0%), education and travel and lodging — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Intuitive Surgical at 49.2% of the total. Reporting peaked in 2024 at $4,237 and has fallen 78.7% since, to $900 in 2025. Among family clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,969in general payments, 2019–2025

Across 146 payments — averaging $47.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$3K
  • AstraZeneca$1K
  • Genmab U.S., Inc.$545
  • Merck$305
  • Eisai Inc.$199
  • GSK$186
  • plus $1K from 23 others

What the payments were for

  • Travel & lodging$1,13616%
  • Food & beverage$3,48450%
  • Education$2,34934%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,969 in reported general payments places this provider in the 95th percentile of 1,080 family providers in New Mexico.

See all family providers in New Mexico

Medicare billing

Part B allowed, 2024
$264,769
Medicare patients
179
Services billed
11,653

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol62$5,055
Estradiol (Twice Weekly)Estradiol29$3,507
DottiEstradiol11$2,010
Naloxone Hcl17$1,101
Levothyroxine Sodium32$947
ProgesteroneProgesterone, Micronized23$723
Clobetasol Propionate11$643
NystopNystatin11$418
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen32$396
Potassium Chloride14$336
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen36$323
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst21$263
Nystatin11$204
Oxycodone Hcl11$202
Gabapentin25$160

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCLevothyroxine Sodium$36$94732 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,080 family providers in New Mexico.

Other family in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →